SAN FRANCISCO: Noetik, a pioneering AI drug discovery company headquartered in San Francisco, has achieved a significant milestone by raising $14 million in seed funding. The company is dedicated to advancing precision therapeutics within the field of immuno-oncology, a vital area of cancer treatment.

Leading the funding round is DCVC, a well-established venture capital firm headquartered in Palo Alto, California. DCVC is known for its investments across various sectors, including biotechnology, where it seeks opportunities in deep tech and other cutting-edge fields such as cybersecurity, climate resilience, and smart agriculture.

Joining DCVC in this strategic funding effort are key investors, including Zetta Venture Partners, 11.2 Capital, Catalio Capital Management, and several others.

Noetik has outlined clear objectives for the utilization of these newly acquired funds. The primary focus will be on supporting data generation initiatives and further enhancing machine learning methods. Additionally, a significant portion of the funding will be allocated to expanding Noetik’s talented team, particularly in the domains of machine learning, computational biology, and cancer immunology.

At its core, Noetik is an AI-native biotechnology firm that has developed a cutting-edge tissue profiling platform. This platform integrates self-supervised learning with spatial biology, positioning itself as a powerful tool to address critical challenges in the realm of cancer immunology. By harnessing the immense potential of self-supervised learning and leveraging human multimodal data, Noetik is determined to pioneer the discovery of more effective precision immunotherapies.

This seed funding represents a pivotal moment for Noetik as it endeavors to push the boundaries of AI-driven drug discovery in the field of immuno-oncology. With its headquarters nestled in San Francisco, CA, Noetik is well-poised to make substantial contributions to the development of novel therapies that promise hope to individuals battling cancer.

As Noetik embarks on its mission to revolutionize cancer treatment through cutting-edge technology, this infusion of capital serves as a testament to the confidence investors have in the company’s vision and capabilities. The path to more precise and effective cancer therapies is becoming clearer with each milestone reached by Noetik.

San Francisco’s Certa raises $35 million in Series B funding to fuel global expansion